These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1694606)

  • 1. Importance of prostatic sonography in the evaluation of conservative therapy of prostatic hyperplasia.
    Fehr JL; Knönagel H
    Urol Int; 1990; 45(4):231-3. PubMed ID: 1694606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Conservative treatment of benign prostatic hyperplasia].
    Romics I
    Orv Hetil; 2008 Oct; 149(40):1875-80. PubMed ID: 18815106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
    Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
    J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dutasteride, who is it more effective for? Second to fourth digit ratio and the relationship with prostate volume reduction by dutasteride treatment.
    Kim TB; Oh JK; Kim KH; Jung H; Yoon SJ; Lee MS; Kim SW
    BJU Int; 2012 Dec; 110(11 Pt C):E857-63. PubMed ID: 22755506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.
    Roehrborn CG; Marks LS; Fenter T; Freedman S; Tuttle J; Gittleman M; Morrill B; Wolford ET
    Urology; 2004 Apr; 63(4):709-15. PubMed ID: 15072886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dual 5-alpha reductase inhibitors in BPH (benign prostatic hyperplasia). Already after 1 month prostate shrinks].
    MMW Fortschr Med; 2003 Feb; 145(9):54. PubMed ID: 12666533
    [No Abstract]   [Full Text] [Related]  

  • 8. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
    Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
    Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Changes in the echostructure of prostatic adenomas during drug therapy].
    Szutrely HP
    Med Klin Prax; 1982 Aug; 77(18):42-6. PubMed ID: 6182449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Benign prostatic syndrome. 3-step plan for the treatment].
    MMW Fortschr Med; 2003 Sep; 145(39):52. PubMed ID: 14649077
    [No Abstract]   [Full Text] [Related]  

  • 13. 5α-Reductase inhibitor is less effective in men with small prostate volume and low serum prostatic specific antigen level.
    Lin VC; Liao CH; Wang CC; Kuo HC
    J Formos Med Assoc; 2015 Sep; 114(9):865-71. PubMed ID: 24064231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Factors determining treatment strategies for patients with benign prostatic hyperplasia. The DUO study].
    Fourcade RO; Picot MC; Gaudin AF; Texier N; Slama A
    Presse Med; 2007 May; 36(5 Pt 1):755-63. PubMed ID: 17329070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of α-blocker monotherapy and α-blocker plus 5α-reductase inhibitor combination therapy based on prostate volume for treatment of benign prostatic hyperplasia.
    Joo KJ; Sung WS; Park SH; Yang WJ; Kim TH
    J Int Med Res; 2012; 40(3):899-908. PubMed ID: 22906262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug therapy for benign prostatic hyperplasia. Systematic overview].
    Berges R; Höfner K
    Urologe A; 2005 May; 44(5):505-12. PubMed ID: 15841355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Murraya koenigii- and Tribulus terrestris-based oral formulation versus tamsulosin in the treatment of benign prostatic hyperplasia in men aged >50 years: a double-blind, double-dummy, randomized controlled trial.
    Sengupta G; Hazra A; Kundu A; Ghosh A
    Clin Ther; 2011 Dec; 33(12):1943-52. PubMed ID: 22177370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrasound image features of intravesical prostatic protrusion indicated failure of medication therapy of finasteride and doxazosin in patients with benign prostatic hyperplasia (LUTS/BPH).
    Liu Q; Zhu Y; Liu J; Qi J; Kang J
    Int Urol Nephrol; 2017 Mar; 49(3):399-404. PubMed ID: 27987130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of intraprostatic architecture and regrowth velocity for considering discontinuation of dutasteride after combination therapy with an alpha blocker: a prospective, pilot study.
    Shindo T; Hashimoto K; Shimizu T; Itoh N; Masumori N
    Korean J Urol; 2015 Apr; 56(4):305-9. PubMed ID: 25874044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suprapubic versus transrectal ultrasonography in assessing the volume of the prostate and the transition zone in patients with benign prostatic hyperplasia.
    Prassopoulos P; Charoulakis N; Anezinis P; Daskalopoulos G; Cranidis A; Gourtsoyiannis N
    Abdom Imaging; 1996; 21(1):75-7. PubMed ID: 8672981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.